- The Asian session brought strong gains across major equity benchmarks; the Nikkei rose more than 1.2%, while Hong Kong’s Hang Seng gained 1.6%. The market focus was on Samsung and SK Hynix deal with OpenAI; SK Hynix shares reached an 25-year high (up 9%), while Samsung gained more than 4%. On the macro side, consumer sentiment in Japan showed a slight improvement, edging up to 35.3 from 35.2 and 34.9 previously.
- The rally in Asia translated into improved sentiment for both European and U.S. index futures, with the US100 climbing 0.25% toward the 25,100 level. At 9 AM GMT, eurozone labor market data will be released, followed by U.S. jobless claims at 12:30 PM GMT and a revision of durable goods orders at 2 PM GMT
- Yesterday’s weaker-than-expected ADP employment data was welcomed by markets, fueling expectations of additional Fed rate cuts later this year. Tomorrow NFP report will be probably delayed, leaving the Fed with quite dovish labour market data, suggesting even 2 more cuts this year.
- According to Goldman Sachs, the likelihood of accelerated economic growth in the U.S. has now increased. On the other hand, S&P Global warned that the ongoing U.S. government shutdown is adding uncertainty to the broader economic outlook.
- Fitch Ratings commented to the US government hutdown: 'A protracted disruption could slightly slow US economic growth. (...) The macroeconomic impact of the shutdown is limited in the near term.' Markets see the shutdown as a potentially dovish, which support gold but impact the US Dollar
- Intel shares gained yesterday after the Semafor informed that the company is now in early talks to add AMD as a foundry customer. Also, Pfizer shares surged more than 6% after upgraded rating by BMO analysts and Politico's report that Trump delayed pharma tariffs to negotiate drug prices.
- Trump last week threatened triple-digit tariffs on pharmaceutical imports beginning Wednesday. The White House now says it may not have to impose them. According to a White House official, the Trump administration has paused its plan to impose the duties in order to negotiate agreements with pharmaceutical giants to avoid higher tariffs on their name-brand products, such as the one announced with Pfizer.
The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.
